Inhibrx Biosciences Signs Deal With Outgoing CSO Brendan Eckelman's New Venture
Inhibrx Biosciences Names David Matly as Pres >INBX
Inhibrx Biosciences Names Carlos Bais as Chief Scientific Officer
Express News | Inhibrx Biosciences Inc - Enters Exclusive License Agreement With New Company
Express News | Inhibrx Biosciences Inc - Brendan Eckelman to Establish New Private Biotech Company as CEO
Express News | Inhibrx Biosciences Announces Departure of Cso and Appointments of New Cso and President
Press Release: Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Express News | Citizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform
JMP Securities Remains a Hold on Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences GAAP EPS of -$3.09 Misses by $0.21, Revenue of $100K
Express News | Inhibrx Q4 Net Income $(47.9)M Or $(3.09) Per Share
Inhibrx Biosciences | 8-K: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Express News | Inhibrx Q4 License Fee Revenue USD 100 Thousand
Express News | Inhibrx Q4 Operating Expenses USD 50.028 Million
Express News | Inhibrx Q4 Operating Income USD -49.928 Million
Express News | Inhibrx Q4 Net Income USD -47.865 Million
Press Release: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Inhibrx Biosciences 4Q Loss/Shr $3.09 >INBX
Inhibrx Biosciences 4Q Rev $100,000 >INBX
Inhibrx Biosciences | 10-K: FY2024 Annual Report